BeiGene has a global workforce of over 9,400 employees. Our team is spread out across 30 countries on five continents.
BeiGene grew its headcount by 15% in 2022. YoY growth can be viewed in the chart below:
- 2022 – 9212
- 2021 – 8033
- 2020 – 5136
- 2019 – 3359
- 2018 – 2070
BeiGene is a global biotechnology company known for discovering and developing innovative oncology medicines that are affordable and accessible to far more patients worldwide.
BeiGene has one of the world’s largest oncology research teams and a broad and deep pipeline with the potential to address 80% of the world’s cancers by type. BeiGene’s small molecule inhibitor of Bruton’s tyrosine kinase (BTK), BRUKINSA, is approved for the treatment of various B-cell malignancies in more than 65 markets across the world.
One of the company’s most advanced investigational medicines is Tislelizumab, a humanized monoclonal antibody directed against the immune checkpoint receptor PD-1 that is currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies.
BeiGene is also known for collaborating with biopharmaceutical companies, including Amgen, Bristol Myers Squibb for Celgene, and Novartis, to develop and commercialize cancer therapies.
BeiGene is traded on three major exchanges – the NASDAQ, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange.
For more information, visit the Stock Information page on the BeiGene website – link here.
Tislelizumab is an anti-PD-1 monoclonal antibody that was discovered by BeiGene. In January 2021, BeiGene partnered with Novartis to accelerate the clinical development and marketing of tislelizumab in the U.S., Europe, and Japan.
BeiGene’s market capitalization is approximately $23 billion and a global workforce of over 9,400 employees as of March 2023. BeiGene has a global presence with operations in Asia, Australia, Europe, Latin America, and North America, and has a growing portfolio of oncology treatments in various stages of development.
BeiGene has offices and operations located across Asia, Australia, Europe, Latin America, and North America. The company’s administrative offices are in Basel, Beijing, and Cambridge, Mass.
BeiGene manufactures and markets:
- Brukinsa (zanubrutinib) – a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) approved for various B-cell malignancies in over 65 countries.
- Tislelizumab (BGB-A317) – a humanized monoclonal antibody directed against the immune checkpoint receptor PD-1 that is currently being investigated as a monotherapy and in combination with other therapies in multiple solid tumors and hematologic malignancies.
- Pamiparib (BGB-290) – a small molecule inhibitor of PARP (poly ADP-ribose polymerase) currently being evaluated for the treatment of ovarian cancer.
BeiGene is a publicly traded global biotechnology company. BeiGene had its IPO on the NASDAQ in February 2016, and is currently traded on the NASDAQ, the Hong Kong Stock Exchange, and the Shanghai Stock Exchange. Amgen, Baker Brothers Advisors, and Capital International Investors are the top three holders of BeiGene.
Brukinsa (zanubrutinib) is manufactured by BeiGene.
John V. Oyler is the Co-Founder, Chairman, and CEO of BeiGene.
John co-founded BeiGene in 2010. He has served as CEO and a member of the Board of Directors from the company’s start, and was appointed board chair when that position was created in 2016.
View John’s full bio here.